{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T12:40:53.236272+00:00","company":{"ticker":"KIDS","cik":1425450,"company_name":"ORTHOPEDIATRICS CORP"},"pagination":{"limit":100,"returned":4,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"754e8e2d73757181c00c637ab4eae0eb108f287a","cik":1425450,"ticker":"KIDS","company_name":"ORTHOPEDIATRICS CORP","filed_at":"2026-04-30T23:59:59+00:00","payload":{"eps_text":"$0.45 per basic and diluted share","guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":"Net loss for the first quarter of 2026 was $10.7 million","period_text":"the first quarter ended March 31, 2026","report_date":"2026-04-30","result_type":"reported_results","revenue_text":"$59.4 million"},"claim":"ORTHOPEDIATRICS CORP reported the first quarter ended March 31, 2026 results: revenue $59.4 million, net income Net loss for the first quarter of 2026 was $10.7 million, EPS $0.45 per basic and diluted share. Guidance raised.","evidence_excerpt":"quarter ended March 31, 2026. First Quarter 2026 and Business Highlights • Helped a record of over 45,000 children in the first quarter of 2026 • Generated total revenue of $59.4 million for the first quarter of 2026, up 13% from $52.4 million in the first quarter of 2025; domestic revenue increased 11% and international revenue increased 22% in the quarter •","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001425450-26-000032","anchor_url":"https://secwatch.observer/filing/0001425450-26-000032#claim-754e8e2d73757181c00c637ab4eae0eb108f287a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1425450/000142545026000032/0001425450-26-000032-index.htm"},{"fact_type":"debt_financing","fact_key":"5f4b2a5e1e0a92d85964269b7f7df6c37e5aa9d1","cik":1425450,"ticker":"KIDS","company_name":"ORTHOPEDIATRICS CORP","filed_at":"2026-04-01T23:59:59+00:00","payload":{"counterparty":"Wilmington Trust, National Association","effective_date":"2026-03-31","event":"amendment","instrument_type":"term_loan","interest_rate_text":"SOFR Interest Rate (with a floor of 3.25%) plus 6.50%","item_codes_triggered":["2.03"],"maturity_text":"August 5, 2029","principal_text":"not to exceed $20.0 million"},"claim":"ORTHOPEDIATRICS CORP amended term loan of not to exceed $20.0 million with Wilmington Trust, National Association at SOFR Interest Rate (with a floor of 3.25%) plus 6.50% maturing August 5, 2029.","evidence_excerpt":"On March 31, 2026, OrthoPediatrics Corp. (the “Company”) and its wholly owned domestic subsidiaries, as borrowers (collectively, the “Credit Parties”), entered into a First Amendment (the “Amendment”) to that certain Credit Agreement and Guaranty (the “Term Loan Agreement”) dated August 5, 2024, by and among the Credit Parties, any additional borrowers from time to time party thereto, any guarantors from time to time party thereto, one or more funds managed by Braidwell LP, as lenders, the other lenders from time to time party thereto, and Wilmington Trust, National Association, as agent. The Amendment provides the Company with incremental committed financing capacity by establishing a new delayed draw term loan facility in an aggregate principal amount not to exceed $20.0 million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-038610","anchor_url":"https://secwatch.observer/filing/0001104659-26-038610#claim-5f4b2a5e1e0a92d85964269b7f7df6c37e5aa9d1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1425450/000110465926038610/0001104659-26-038610-index.htm"},{"fact_type":"material_agreement","fact_key":"a83aff381a1ba892729291728cd6fd856a095fc8","cik":1425450,"ticker":"KIDS","company_name":"ORTHOPEDIATRICS CORP","filed_at":"2026-04-01T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"First Amendment","agreement_type":"credit_facility","counterparty":"Braidwell LP","effective_date":"2026-03-31","item_codes_triggered":["1.01"],"value_text":"$20.0 million"},"claim":"ORTHOPEDIATRICS CORP amended First Amendment with Braidwell LP valued at $20.0 million (effective 2026-03-31).","evidence_excerpt":"On March 31, 2026, OrthoPediatrics Corp. (the “Company”) and its wholly owned domestic subsidiaries, as borrowers (collectively, the “Credit Parties”), entered into a First Amendment (the “Amendment”) to that certain Credit Agreement and Guaranty (the “Term Loan Agreement”) dated August 5, 2024, by and among the Credit Parties, any additional borrowers from time to time party thereto, any guarantors from time to time party thereto, one or more funds managed by Braidwell LP, as lenders, the other lenders from time to time party thereto, and Wilmington Trust, National Association, as agent.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-038610","anchor_url":"https://secwatch.observer/filing/0001104659-26-038610#claim-a83aff381a1ba892729291728cd6fd856a095fc8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1425450/000110465926038610/0001104659-26-038610-index.htm"},{"fact_type":"earnings_release","fact_key":"f1ec903538092f0cb9e8eda3c38e9c6c444880f4","cik":1425450,"ticker":"KIDS","company_name":"ORTHOPEDIATRICS CORP","filed_at":"2024-05-06T23:59:59+00:00","payload":{"eps_text":"$0.34 per basic and diluted share","guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":"$7.8 million","period_text":"the first quarter ended March 31, 2024","report_date":"2024-05-06","result_type":"reported_results","revenue_text":"$44.7 million"},"claim":"ORTHOPEDIATRICS CORP reported the first quarter ended March 31, 2024 results: revenue $44.7 million, net income $7.8 million, EPS $0.34 per basic and diluted share. Guidance raised.","evidence_excerpt":"Quarter 2024 and Business Highlights • Helped nearly 28,000 children in the first quarter of 2024, an increase of 47% from the first quarter 2023 • Generated total revenue of $44.7 million for the first quarter of 2024, up 41% from $31.6 million in first quarter 2023; domestic revenue increased 44% and international revenue increased 33% in the quarter • Grew","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001425450-24-000031","anchor_url":"https://secwatch.observer/filing/0001425450-24-000031#claim-f1ec903538092f0cb9e8eda3c38e9c6c444880f4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1425450/000142545024000031/0001425450-24-000031-index.htm"}]}